Summit Therapeutics PLC’s (SMMT) Buy Rating Reiterated at Canaccord Genuity

Summit Therapeutics PLC (NASDAQ:SMMT)‘s stock had its “buy” rating reissued by equities research analysts at Canaccord Genuity in a report issued on Monday.

Several other equities analysts have also recently issued reports on the stock. Zacks Investment Research raised shares of Summit Therapeutics PLC from a “hold” rating to a “buy” rating and set a $13.00 price objective on the stock in a research note on Tuesday, July 4th. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $24.00 price objective on shares of Summit Therapeutics PLC in a research note on Monday, September 11th. Finally, ValuEngine cut shares of Summit Therapeutics PLC from a “hold” rating to a “sell” rating in a research note on Thursday, October 5th. Two investment analysts have rated the stock with a sell rating and three have issued a buy rating to the company’s stock. Summit Therapeutics PLC currently has an average rating of “Hold” and an average target price of $23.50.

Shares of Summit Therapeutics PLC (SMMT) traded down 2.10% during mid-day trading on Monday, hitting $12.13. 45,729 shares of the company’s stock traded hands. The stock has a 50 day moving average price of $12.92 and a 200-day moving average price of $12.92. Summit Therapeutics PLC has a 1-year low of $7.95 and a 1-year high of $16.86. The stock’s market cap is $150.23 million.

Summit Therapeutics PLC (NASDAQ:SMMT) last announced its quarterly earnings data on Thursday, August 31st. The company reported $1.10 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.38 by ($0.28). The business had revenue of $25.01 million during the quarter, compared to analyst estimates of $31.37 million. Summit Therapeutics PLC had a negative return on equity of 29,334.40% and a negative net margin of 12.44%. Equities research analysts anticipate that Summit Therapeutics PLC will post ($0.08) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://ledgergazette.com/2017/10/16/summit-therapeutics-plcs-smmt-buy-rating-reiterated-at-canaccord-genuity.html.

An institutional investor recently bought a new position in Summit Therapeutics PLC stock. Renaissance Technologies LLC purchased a new position in shares of Summit Therapeutics PLC (NASDAQ:SMMT) in the 1st qu

Several other equities analysts have also recently issued reports on the stock. Zacks Investment Research raised shares of Summit Therapeutics PLC from a “hold” rating to a “buy” rating and set a $13.00 price objective on the stock in a research note on Tuesday, July 4th. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $24.00 price objective on shares of Summit Therapeutics PLC in a research note on Monday, September 11th. Finally, ValuEngine cut shares of Summit Therapeutics PLC from a “hold” rating to a “sell” rating in a research note on Thursday, October 5th. Two investment analysts have rated the stock with a sell rating and three have issued a buy rating to the company’s stock. Summit Therapeutics PLC currently has an average rating of “Hold” and an average target price of $23.50.

Shares of Summit Therapeutics PLC (SMMT) traded down 2.10% during mid-day trading on Monday, hitting $12.13. 45,729 shares of the company’s stock traded hands. The stock has a 50 day moving average price of $12.92 and a 200-day moving average price of $12.92. Summit Therapeutics PLC has a 1-year low of $7.95 and a 1-year high of $16.86. The stock’s market cap is $150.23 million.

Summit Therapeutics PLC (NASDAQ:SMMT) last announced its quarterly earnings data on Thursday, August 31st. The company reported $1.10 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.38 by ($0.28). The business had revenue of $25.01 million during the quarter, compared to analyst estimates of $31.37 million. Summit Therapeutics PLC had a negative return on equity of 29,334.40% and a negative net margin of 12.44%. Equities research analysts anticipate that Summit Therapeutics PLC will post ($0.08) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://ledgergazette.com/2017/10/16/summit-therapeutics-plcs-smmt-buy-rating-reiterated-at-canaccord-genuity.html.

An institutional investor recently bought a new position in Summit Therapeutics PLC stock. Renaissance Technologies LLC purchased a new position in shares of Summit Therapeutics PLC (NASDAQ:SMMT) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 20,102 shares of the company’s stock, valued at approximately $267,000. Renaissance Technologies LLC owned 0.16% of Summit Therapeutics PLC as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 21.77% of the company’s stock.

Summit Therapeutics PLC Company Profile

Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).

Receive News & Ratings for Summit Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply